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Hepatitis B and C viruses are human  pathogens of major significance. Their 
extrahepatic manifestations are global health problem. HBV is a well-known cause of 
membranous nephropathy, membranoproliferative GN and IgA nephropathy, frequently 
in Asian populations. Polyarteritis nodosa is a rare, but serious systemic complication of 
chronic HBV. Immunosuppressive therapy in HBV-related GN is not recommended.   
Interferon alpha treatment produces sustained remission of porteinuria, often associated 
with clearance of HBeAg and/or HBsAg, however, it has many side effects. Compared to 
interferon, nucleos(t)ide analogues offer some advantages. These antiviral agents 
suppress HBV replication through their inhibitory effect on viral DNA polymerase.  They 
have convenient administration and high tolerability. Lamivudine is well tolerated and 
safe in long-term studies, but the resistance of HBV is an escalating problem. The 
resistance to newer polymerase inhibitors Entecavir and Tenofovir is significantly lower.  
Hepatitis C virus causes cryoglobulinemia-mediated glomerulonephritis and  other 
immune complex forms of GN. The renal manifestations are usually associated with 
long-lasting HCV infection. HCV glomerular disease is more frequent in adult males, and 
often leads to chronic renal insufficiency. The first line treatment in patients with mild to 
moderate clinical and histological kidney damage is the antiviral therapy with pegylated 
INF alpha and ribavirin. In case of severe HCV-associated cryoglobulinemic GN - 
nephrotic syndrome, nephritic syndrome and/or progressive renal failure, high activity 
score of glomerulonephritis on light microscopy, the initial treatment might consist of 
sequential administration of antiviral and immunosuppressive agents (corticosteroids, 
cyclophosphamide and plasma exchange), or rituximab. The treatment of HCV-related 
glomerular disease is still under debate and based on scant experimental evidence. 
Large randomized and controlled clinical trials are needed to establish guidelines for the 
treatment of HCV-related cryoglobulinemic glomerulonephritis. Acta Medica Medianae 
2014;53(1):58-64. 
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Introduction 
 
The problem about renal involvement in 
HBV and HCV infection has several different 
aspects. The first of them concerns immune 
mediated glomerular or vascular disease related 
to HBV and HCV. From an opposite perspective, 
HBV and HCV  infections have a critical impact on 
morbidity, survival and QL of patients with CKD, 
especially those with ESRD on dialysis, the 
clinical course of kidney transplant recipients and 
patients with renal diseases who are treated with 
immunosuppressive drugs. Finally, the effect of 
antiviral therapy on renal function must be taken 
into account: in patients with chronic liver 
disease, in patients with CKD, after liver trans-
plantation and after kidney transplantation. 
Hepatitis B virus (HBV) infection 
 
Hepatitis B virus is a human pathogen of 
major significance. HBV infection and its compli-
cations are global health problems. HBV is esti-
mated to have infected about 400 million people 
worldwide. The proportion of HBsAg positivity 
(chronic HBV carriers) in the general population 
varies from 1% in nonendemic areas to 10% in 
South East Asia. Every year, one million people in 
Europe are infected with HBV. Renal involvement 
is among its most common extra hepatic mani-
festations. 
 
HBV immunopathogenesis 
 
HBV is a small enveloped DNA virus 
belonging to the Hepadna family. It is composed 
of an outer envelope of host-derived lipid 
containing the surface proteins and an inner 
protein capsid that contains the genomic DNA 
(1). The capsid is composed of a single poly-
peptide chain, molecular weight 20 kDa, known 
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Hepatits B virus causes necroinflammatory 
liver disease of variable duration and severity, 
from asymptomatic HBsAg carrier state to 
chronic hepatitis with progression to cirrhosis, 
end-stage liver disease and hepatocellular carci-
noma. HBV is not directly cytopathic. The host 
immune response to HBV-encoded antigens is 
responsible both for viral clearance and disease 
pathogenesis. HBV capsids are highly antigenic, 
eliciting a strong response with B cells, T helper 
cells and cytotoxic T cells.  
The cellular immune response (especially 
the cytotoxic T lymphocytes) eliminates infected 
cells. HBV-specific cytotoxic T-lymphocytes can 
downregulate HBV gene expression and repli-
cation by INF gamma, TNF alpha and IL2. The 
cellular immune response determines the clinical 
course of viral infection: the T cell response to 
the virus is vigorous in acutely infected patients, 
who successfully clear the virus, but the response 
is relatively weak and more narrowly focused in 
chronically infected patients who do not, 
especially with neonatal exposure to HBV. 
The humoral antibody response to viral 
envelope antigens contributes to the clearance of 
circulating viral particles. With persistent viral 
infection, the heightened immune response 
favors formation of circulating immune com-
plexes. Circulating antigen-antibody complexes 
are important in the pathogenesis of extrahepatic 
disease manifestations (3, 4). 
Extrahepatic manifestations in acute or 
chronic hepatitis B appear to be immune-
mediated (4, 5):  
• Transient serum sickness-like syndrome; 
• Polyarteritis nodosa; 
• Glomerulonephritis; 
• Arthralgia; 
• Papular acrodermatitis in children (Gianotti-
Crosti syndrome);  
• Palpable purpura. 
No correlation between HBV genotypes and 
the presence of extrahepatic manifestations has 
been found. 
 
Glomerulonephritis in association  with 
HBV infection 
 
Brzosko et al. (6) in 1974 were the first to 
suggest that HBV might be involved in the 
pathogenesis of high percentage of glomerulo-
nephritis (GN) and found an incidence of 34.6% 
with various types of glomerular diseases. 
Subsequently similar incidence was reported by 
Nagy et al. (7). Over the last few years, various 
morphologic patterns of HBV related GN have 
been reported, with membranous nephropathy 
(MN) being the most commonly described. The 
importance of HBV in renal pathology is markedly 
higher in areas with endemic infection such as 
South East Asia than in Europe and USA. 
Pure forms of glomerulonephritis or, 
occasionally, in overlapping forms have been 
seen in association with HBV infection: 
•  Membranous nephropathy (MN); 
•  Membranoproliferative glomerulonephritis 
(MPGN) ; 
•  Mesangioproliferative IgA nephropathy 
(IgAN); 
•  Focal and segmental glomerulosclerosis 
(FSGS). 
 
Pathogenesis of GN associated with HBV 
 
Both viral and host factors are involved. A 
prevalence of genotype A in patients with HBV-
related nephropathy has been described. Also, an 
association with HLA genes has been reported. 
GN appears to be immune-mediated: deposition 
of circulating immune complexes, containing 
HBsAg or HBeAg in antigen excess; induction of 
local immune complex formation by viral 
antigens; viral-induced autoantibodies reacting 
with tissue antigens; direct viral reaction to 
kidney tissue sites (8). 
HBx protein can up-regulate CD59 expression 
in podocytes resulting in decreased complement 
activation, which may facilitate latent HBV 
infection in podocytes and play a role in 
development of hepatitis B virus associated GN. 
In experimental studies HBsAg and HBcAg 
expressed in the cytoplasm of renal tubular 
epithelial cells without replication of the whole 
virus upregulated complement and coagulation 
pathways and acute phase response genes, and 
reduced the circulating C3 levels. Circulating 
HBV-DNA in HBV carriers was found to induce 
TGF beta, apoptosis of tubular epithelial cells and 
fibrosis (8,9). It has been reported that the sera 
of patients with chronic HBV infection could 
induce apoptosis in cultured cell line for the study 
of human proximal renal tubular epithelial cells, 
via up-regulation of Fas gene expression (10). 
Furthermore, the induction of apoptosis correlated 
with the level of circulating HBV DNA, and HBV 
carriers also showed a higher circulating level of 
TGF-beta, a growth factor implicated in the 
potentiation of apoptosis and renal fibrosis. 
Autoimmune disorders have also been 
observed among certain susceptible vaccine 
recipients: 
•  Arthritis, including rheumatoid arthritis; 
•  Myelitis; 
•  Optic neuritis; 
•  Glomerulonephritis; 
•  Pancytopenia or thrombocytopenia;  
•  MS. 
 
Membranous nephropathy (MN) 
 
MN is the most commonly described 
glomerular disease in association with HBV. It 
occurs mainly in children, predominantly in males 
in HBV endemic areas (Asian populations) (11).  
The reported prevalence of HBV-associated 
MN closely parallels the geographic patterns of 
prevalence of HBV. In South East Asia, where the 
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10% in the general population, HBV is the under-
lying cause in 12% of patients with membranous 
nephropathy. The rarity of HBV-associated nephro-
pathy in developed countries such as the USA 
and Europe probably reflects the rarity of HBV 
infection, particularly in children. In developed 
countries, HBV-associated nephropathy is frequently 
seen in adults who are high-risk groups such as 
intravenous drug abusers and in dialysis patients. 
Introduction of HBV immuni-zation was one of 
the principle factors in lowering the incidence of 
HBV-associated nephropathy (12). 
HBV-related membranous nephropathy is 
characterized by thickened capillary wall and 
glomerular basement membrane on light micro-
scopy. Mesangial abnormalities are more common 
compared to the idiopathic form, and deposits of 
membrane attack complex (C5b-9) in glomerular 
subepithelium are lower compared to idiopathic 
MN. Immunofluorescent staining and electron 
microscopy demonstrate subepithelial deposition 
of immune complexes containing HBsAg and 
HBeAg, IgG, C3 and IgM, extensive effacement of 
the podocyte foot processes, and in some cases 
viral particles in various locations within the 
glomerulus. 
The clinical presentation of HBV-related MN 
is in most cases a nephrotic syndrome. In the 
asymptomatic cases proteinuria, impairment of 
renal function and hypertension have been found. 
In children it is usually self-limited, in 60-85% by 
2 years, in 95% by 5-7 years. Only rare pro-
gression to renal failure is observed. Liver tests 
are frequently normal. In adults, the natural 
course of GN may be more relentless, slowly 
progressing to renal failure in about 30-50% of 
patients (4,12).   
 
HBV-associated membranoproliferative 
GN 
 
HBsAg has been detected with MPGN and 
IgAN patients. The pathogenesis of MPGN most 
likely involves deposition of circulating IC 
containing HBV antigens in glomeruli, due to 
persistent viral infection, in which the heightened 
immune response favors formation of circulating 
IC's, with ultimate deposition into extrahepatic 
sites (13). 
Histopathologically, MPGN is associated 
with mesangial and capillary wall deposits of 
HBsAg. Dense deposits bearing HBsAg immuno-
reactivity in a thickened glomerular basement 
membrane have been found. IgG, complement 
components, and IgM appear granular on immuno-
fluorescent staining, located in the subendo-
thelial, mesangial, and paramesangial areas.  
Impaired renal function is more common in 
patients with membranoproliferative glomerulo-
nephritis compared to membranous nephropathy. 
 
HBV-associated IgA nephropathy 
 
It is more frequent in adults, predomi-
nantly in Eastern Asia (up to 34% HBsAg posi-
tivity in patients with IgAN in China).  
On immunofluorescence, mesangial IgA 
deposition in association with IgG subepithelial 
deposits, giving a combination of MGN and IgAN 
have been  found (14). Immunohistochemically, 
HBeAg, HBsAg and HBcAg have been detected in 
glomeruli, tubular epithelial cells and infiltrating 
interstitial lymphocytes.  
Electron microscopy frequently shows tubu-
loreticular inclusions, located within dilated 
cisternae of the endoplasmic reticulum belonging 
to the endothelial cell cytoplasm of glomerular 
and peritubular capillaries. They are the ex-
pression of endogenous virus-induced interferon 
production. Moreover, HBV-DNA has been detec-
ted by in situ hybridization and Southern blot 
analysis in the nuclei of mesangial and tubular 
epithelial cells. These facts lead to the suggestion 
that not only  immune complex deposition play a 
role in the pathogenesis of IgA nephropathy 
associated with HBV, but also cellular mecha-
nisms mediated by direct infection of renal tissue 
with HBV (15). 
 
Focal and segmental glomeruloscle-
rosis (FSGS) in  association with HBV 
infection 
 
Only a few cases have been reported till 
now. HBsAg was demonstrated in renal tissue of 
2 cases. HBV-DNA has been detected in urinary 
podocytes by real-time PCR methods. They 
showed response to treatment with lamivudine, 
thus indicating a possible causal association 
between the viral infection and occurrence of 
nephrotic syndrome. After the anti-viral therapy 
FSGS improved, paralleling the decreased level of 
HBV-DNA in podocytes (16,17).  
 
Diagnostic criteria for HBV-associated 
GN 
 
It is difficult to asses the relation between 
HBV and GN because of the high frequency of 
HBV asymptomatic carriers in the general 
population. Diagnosis is based on the presence of 
persistent HBV antigenemia and tissue molecular 
analysis - detection of at least one HBV antigen 
in renal tissue by a monoclonal F(ab) antibody 
method. The spontaneous remission of glo-
merulonephritis after successful treatment of HBV 
infection favors an etiopathogenic link between 
HBV and GN . Spontaneous remission is usually 
associated with seroconversion of HBeAg (4). 
 
Treatment of HBV - associated GN 
 
The uncommon occurrence and small 
series, variability in renal histopathology, and 
heterogeneity in clinical course lead to uncer-
tainty with regard to the optimal management of 
HBV-related GN. Much of the data on the 
treatment of HBV-related glomerular diseases 
came from patients with membranous nephro-
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merulonephritis or focal segmental glomeru-
losclerosis remain anecdotal. 
Immunosuppressive therapy in HBV-related 
GN is not recommended. The available evidence 
does not support the  use of corticosteroids in 
HBV-associated MN. They enhance viral repli-
cation and precipitate hepatic flares. The use of 
rituximab has resulted in HBV reactivation, the 
severity of which has resulted in death in some 
patients (18). 
Antiviral treatment of HBV associated GN. 
Results in adults are less favorable compared 
with children. Patients who do not clear the virus 
usually develop progressive renal failure.  
Conventional and pegylated interferon-α 
(INF-α) possess both immunoregulatory and 
antiviral effects (19). INF-α  activates  cellular 
pathways that lead to breakdown of viral RNA 
and enhances cell-mediated immune response 
toward hepatocytes infected with HBV. Interferon 
treatment 4-12 months produces sustained 
remission of proteinuria in 20 to 100% of patients. 
Resolution of proteinuria is often associated with 
clearance of HBeAg and/or HBsAg, and usually 
occurs within six months of seroconversion (12). 
The treatment with INF-α has many side effects: 
flu-like syndrome, fatigue, headache, muscle 
pain, appetite loss, alopecia, depression, bone 
marrow aplasia, bacterial infection, autoimmune 
thyreoiditis, diarrhea, rash and it is self limited. 
Compared to interferon, nucleos(t)ide 
analogues offer some advantages. These antiviral 
agents suppress HBV replication through their 
inhibitory effect on viral DNA polymerase. They 
have convenient administration and high tolera-
bility, but the treatment is long-term: 
•  nucleoside analogues: Lamivudine 100 
mg p.o. daily; Telbivudine 600mg p.o. daily; 
Entecavir 0,5mg p.o. daily 
•  nucleotide analogues, such as: Adefovir 
dipivoxil 10mg p.o. daily; Tenofovir 300mg p.o. 
daily. 
Lamivudine, usualy at a dose of 100mg 
once daily, is well tolerated and safe in long-term 
studies. It leads to seroconversion of HBsAg and 
HBeAg to anti-HBs and anti-HBe and remission of 
nephrotic syndrome in MN.  An international data 
analysis showed that the majority of patients 
using lamivudine experienced remissions com-
pared to those receiving other treatment 
modalities (20,21). 
Only pilot studies on the new DNA-poly-
merase inhibitors are available, pre-dominantly in 
CKD and transplanted patients. A slight impair-
ment of renal proximal-tubular function has been 
described with Adefovir (12,20-22). Tenofovir, 
more potent than adefovir, has been reported to 
cause Fanconi syndrome and kidney failure. 
Entecavir appears to be more safe in patients 
with kidney diseases. 
Long-term treatment of chronic hepatitis B 
with nucleos(t)ide analogs, especially with  Lami-
vudine, can lead to the emergence of HBV 
resistant mutants of the polymerase gene. Nowa-
days, the resistance is an escalating problem. 
The resistance of HBV to newer polymerase 
inhibitors Entecavir and Tenofovir is significantly 
lower. 
 
Hepatitis B virus-associated polyarte-
ritis nodosa (PAN)  
 
PAN is a rare, but serious systemic 
complication of chronic HBV. Only 1% or less of 
the total population of patients who are HBsAg 
positive develops PAN. Analysis of the HBV 
genome revealed no mutations that could be 
associated with PAN (4). 
Pathogenesis has been attributed to 
immune-complex deposition with antigen excess. 
Surface antigen-antibody complexes are depo-
sited in vascular beds. Complement activation 
promotes inflammation mainly by production of 
chemotactic factors, which direct the migration of 
polymorphonuclear leukocytes and monocytes 
and by release of anaphylatoxins (C3a and C5a), 
which increase vascular permeability. Leukocytes 
are activated by the engagement of their C3b 
and Fc receptors by the immune complexes. This 
results in the release or generation of pro-
inflammatory substances, including prostaglan-
dins, vasodilatory peptides, chemotactic sub-
stances, oxygen free radicals and lysosomal 
enzymes. Immune complexes also cause aggre-
gation of platelets and activation of Hageman 
factor and initiate the formation of microthrombi 
(4,23). 
Polyarteritis may occur at any time in 
patients who are HBsAg positive. It represents a 
typical form of classic PAN: systemic necrotizing 
vasculitis without glomerulonephritis. ANCA are 
not detected. Orchitis is more frequent in HBsAg 
positive patients with PAN. The major cause of 
death is gastrointestinal tract involvement. 
Frequency of HBV-PAN has decreased 
significantly in relation to improved blood safety 
and vaccination campaigns (24). 
 
Treatment of HBV-associated PAN  
 
Antiviral therapy with interferon-alpha and 
lamivudine causing seroconversion leads to 
remission. Combining an antiviral drug with 
plasma exchange facilitates seroconversion and 
prevents the development of long-term hepatic 
complications of HBV infection. Clinical remission 
of PAN was observed in treated patients, but in 
none of the patients who were not receiving 
antiviral medication. Relapses are rare, and 
never occur once viral replication has stopped 
and seroconversion has been obtained (24).   
 
Hepatitis C virus (HCV) infection 
 
HCV is the major etiologic agent of chronic 
hepatitis and possible liver cirrhosis and hepa-
tocarcinoma. It represents an enveloped RNA 
virus belonging to the Flaviviridae family. It 
possesses high genomic variability (6 genotypes, 
over 100 subtypes) and high dynamics. Glomerular diseases associated with HBV and HCV infection                                                                              Boriana Kiperova 
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Extrahepatic manifestation of HCV 
infection  
 
Patients with chronic HCV infection are at 
risk of a great number of extrahepatic mani-
festations (EHMs) –  up to 40-76% of patients 
infected with HCV develop at least one EHM 
during the course of the disease. EHMs are often 
the first and only clinical sign of chronic hepatitis 
C infection: mixed cryoglobilinaemia, cryoglobu-
linaemic vasculitis, peripheral neuropathy, mem-
brano-proliferative glomerulonephritis, membranous 
nephropathy, rheumatoid arthral-gias/oligo-poly-
arthritis, autoimmune thyreoiditis, insulin  resis-
tance/diabetes mellitus, lympho-proliferative dis-
orders/non-Hodgkin lymphomas, immune thrombo-
cytopaenic purpura, monoclonal gammopathies, 
autoimmune haemolytic anaemia, dermatologic 
disorders, porphyria cutanea tarda, myopathy, 
cardiomyopathy/myocarditis, idiopatic pulmonal 
fibrosis (25). 
 
Pathogenic mechanisms 
 
The pathogenesis of EHM is still not fully 
understood. HC virus avoids immune elimination 
and the consequence is chronic infection.  HCV, 
replicating and expressing viral proteins in 
extrahepatic tissues, leads to accumulation of 
circulating immune complexes and autoimmune 
phenomena. Most studies suggest that the 
presence of mixed cryoglobulinaemia, particular 
lymphotropism of the virus, molecular mimicry 
and non-cryoglobulinaemic autoimmune pheno-
mena constitute the major pathogenic factors 
(25). 
There are two types of HCV-associated 
glomerular diseases:  
•  HCV-associated cryoglobulinemic glome-
rulonephritis; 
•  Immune-complex disease with HCV-
containing immune complexes: 
- Membranoproliferative GN,  
- Membranous nephropathy. 
Mixed cryoglobulinemia (MC) type II and 
III is the most known and studied syndrome 
associated with HCV infection. It is found in 19%-
50% of patients with chronic HCV, but leads to 
clinical manifestations through vascular pre-
cipitation of immunocomplexes, in only 30% of 
them and causes systemic vasculitis of small and 
medium sized blood vessels that may involve the 
skin, kidney  and nervous system. In 95% of 
cases with so-called “essential” MC anti-HCV Ab, 
HCV RNA in plasma and  in cryoprecipitates are 
found. 
Histopathologically, in membranoprolife-
rative cryoglobulinemic glomerulonephritis glomeruli 
show accentuated lobulation, mesangial cellu-
larity, mesangiolysis, capillary endothelial swelling 
and splitting of capillary basement membranes. 
There is a marked infiltration of glomerular 
capillaries by leukocytes. PAS stain highlights 
intracapillary aggregates of immune complexes 
involving cryoglobulins. Electron micrograph 
demonstrates subendothelial immune deposits, 
with some fibrillar organization (26, 27).  
In non-cryoglobulinemic MPGN the patern 
is similar, but mesangiolysis, leukocyte influx and 
intracapillary accumulation are  les likely to be 
apparent. Both subendothelial and subepithelial 
immune complexes can be identified by electron 
microscopy (28). 
The renal manifestations are usually 
associated with long-lasting HCV infection, longer 
than 10-year history. Most often, there are 
clinical and laboratory features of chronic active 
hepatitis and/or cirrhosis. HCV glomerular disease 
is more frequent in adult males, it is rare in 
children. 
In mixed cryoglobulinaemia, patients usually 
have palpable purpura, arthralgia, neuropathy. 
Rarely, the presentation may include severe 
vasculitis with abdominal pain and other solid 
organ involvement. Renal manifestation includes 
nephrotic or non-nephrotic proteinuria and micro-
scopic hematuria. Renal insufficiency is commonly 
identified. Laboratory tests demonstrate viraemia 
(circulating HCV DNA by PCR analysis), low C3 
and C4, mixed cryoglobulinaemia and  positive 
rheumatoid factor, ANCA negativity (25). 
The clinical evolution is slow, in about 30% 
renal function is maintained for many years. In 
10-15% clinical regression has been observed, 
recurrent episodes in 20% and end stage renal 
disease in 15%. Recurrence of MPGN in allografts 
has been suspected in a small number of 
patients, but this problem has not yet adequately 
studied. 
Small series of membranous nephropathy 
have been reported in HCV-infected patients 
(29). 
HIV-HCV co-infection may be seen nowadays, 
presenting with nephrotic syndrome and some-
times with immunotactoid deposits. 
 
Treatment of HCV-associated cryo-
globulinemic glomerulonephritis  
 
Results of treatment of these patients with 
interferon alone have been disappointing, since 
relapse of the viraemia and subsequent relapse 
of the renal disease are major problems. 
Combination of interferon with ribavirin has been 
shown to increase the rate of sustained response.  
The first line treatment in patients with 
mild to moderate clinical and histological kidney 
damage is the antiviral therapy with pegylated 
INF alpha and ribavirin for at least 48 weeks. A 
significant benefit has been reported with this 
regimen. Ribavirin doses should be adapted 
according to creatinine clearance in order to 
avoid its main side effect, i.e. hemolytic anemia. 
(25,30-32).  
In patients on regular dialysis, mono-
therapy with conventional interferon without 
ribavirin is recommended, while after renal 
transplantation interferon must not be used 
except for dire circumstances. Acta Medica Medianae 2014, Vol.53(1)                                                 Glomerular diseases associated with HBV and HCV infection 
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In case of severe HCV-associated cryoglo-
bulinemic GN - nephrotic syndrome, nephritic syn-
drome  and/or progressive renal failure, high 
activity score of glomerulonephritis on light 
microscopy, the initial treatment might consist of 
sequential administration of antiviral and immuno-
suppressive agents or rituximab (30,32). Immuno-
suppressive therapy consists of plasma exchange 
(in acute manifestation), corticosteroids for a 
short period and mild dosage cyclophosphamide 
in life-threatening organ involvement when there 
is no response to steroids. 
In refractory or intolerant patients the 
alternative to conventional therapy is B-cell de-
pleting agent anti-CD20, rituximab. Drug-induced 
viral load elevation is of minor extent after this 
treatment.  
 
The vaccination campaigns on large popu-
lations worldwide lead to a decrease in HBV 
infection and its extrahepatic consequences. 
The problem of HCV infection remains 
unsolved, the prevalence of HCV seropositivity is 
stable and associated kidney disease is of poten-
tial magnitude. The precise pathogenic sequence 
of injury resulting in glomerulonephritis is not 
known. The treatment  is still under debate and 
based on scant experimental evidence. No 
definitive data are yet available from the lite-
rature. Large randomized and controlled clinical 
trials are needed to establish guidelines for the 
treatment of HCV-related cryoglobulinemic glo-
merulonephritis.  
Moreover, the management of HBV and 
HCV infections in CKD and kidney transplanted 
patients remains a challenge to nephrologists. 
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GLOMERULARNA OBOLJENJA POVEZANA SA HBV I HCV INFEKCIJAMA 
 
Boriana Kiperova 
 
 
Virusi hepatitisa B i C predstavljaju glavne patogene kod ljudi. Njihove 
ekstrahepatične manifestacije su globalni zdravstveni problem. HBV je dobro poznati 
uzrok membranozne nefropatije, membranoproliferativne GN i IgA nefropatije koje su 
česte među stanovništvom Azije.  Polyarteritis nodosa je retka ali ozbiljna sistemska 
komplikacija  hroničnog  HBV.  Imunosupresivna  terapija kod glomerolunefritisa 
povezanog sa HBV se ne preporučuje.  Lečenje  interferonom  alfa stvara remisiju 
porteinurije, ćesto udružene sa oslobađanjem HBeAg i/ili HBsAg, ali ona ima mnoga 
neželjena  dejstva.  U  poređenju  sa  interferonom,  analozi  nukleotida  pružaju  neke 
prednosti. Ovi  antivirusni  agenti  suprimiraju  razmnožavanje  HBV  preko  svog 
inhibitornog dejstva na virusnu DNA polimerazu. Oni se lako administriraju i dobro se 
tolerišu.    Dugoročne  studije  su  pokazale  da  je  Lamivudine  bezbedan  i  da  se  dobro 
podnosi, ali je otpornost HBV veliki problem. Otpornost na novije inhibitore polimeraze 
Entecavir i Tenofovir je značajno niža. Virus hepatitisa C uzrokuje krioglobulinemiju i 
druge  imunski  složene  oblike  GN.  Renalne  manifestacije  su  obično  udružene  sa 
dugotrajnom HCV infekcijom. Glomerularno oboljenje HCV  češće  je  kod odraslih 
muškaraca i često dovodi do hronične renalne insuficijencije. Prva linija lečenja kod 
bolesnika  sa  blagim  do  umerenim  kliničkim  i  histološkim  oštećenjem  bubrega  jeste 
antivirusna terapija sa peginterferon alfa  2a  i  ribavirinom.  U  slučaju  teškog 
krioglobulinemijsko GN nefritičnog sindroma povezanog sa HCV, nefritičnog sindroma 
i/ili progresivne renalne disfunkcije, visokog ukupnog dejstva glomerulonefritisa na 
svetlosnom mikroskopu, početno lečenje bi se sastojalo od naizmenične administracije 
antivirusnih i imunosupresivnih supstanci (kortikosteroidi, ciklofosfamidi i razmena 
plazme ili rituximaba). O lečenju glomerularnog oboljenja povezanog sa HCV još se 
uvek vode rasprave, a i ne postoji dovoljno eksperimentalnih dokaza o tome. Potrebno 
je  izvesti  velika  klinička  randomizirana  i  kontrolna  ispitivanja  kako  bi  se  odredila 
uputstva za lečenje krioglobulinemijskog glomerulonefritisa povezanog sa  HCV. Acta 
Medica Medianae 2014;53(1):58-64. 
 
Ključne  reči::  Virus hepatitisa B, virus hepatitisa C, glomerularno oboljenje, 
antivirusno lečenje 